Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

TERMINATION OF DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION OF NEW SHARES IN BRONCUS

This announcement is made by Shanghai INT Medical Instruments Co., Ltd.* (上海瑛泰醫療器械股份有限公司) (the "**Company**") pursuant to Rule 14.36 of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Reference is made to the announcement of the Company dated 10 October 2025 (the "**Announcement**") in relation to the subscription of 91,093,613 new shares in Broncus Holding Corporation ("**Broncus**", stock code: 2216) at a subscription price of HK$3.11 per Subscription Share for a total consideration of HK$283,301,136.43 pursuant to the subscription agreement dated 10 October 2025 entered into between the Company and Broncus (the "**Subscription Agreement**"). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The board of directors (the "**Board**") of the Company hereby announces that on 26 May 2026 (after trading hours), the Company and Broncus entered into a termination agreement (the "**Termination Agreement**"), pursuant to which the parties have mutually agreed to terminate the Subscription Agreement and the transactions contemplated thereunder. Under the Termination Agreement, all obligations and liabilities under the Subscription Agreement are fully and irrevocably released and discharged (except the confidentiality obligations thereunder), and neither party shall have any claim against the other in respect thereof (except the confidentiality obligations thereunder). As at the date of this announcement, no consideration has been paid by the Company to Broncus under the Subscription Agreement.

The Board is of the view that the termination of the Subscription Agreement will not have any material adverse impact on the financial position and operations of the Group and is in the interests of the Company and the Shareholders as a whole.

By order of the Board
Shanghai INT Medical Instruments Co., Ltd.*
上海瑛泰醫療器械股份有限公司
Dr. Liang Dongke
Chairman

Shanghai, the PRC
26 May 2026

As at the date of this announcement, the Board comprises Dr. Liang Dongke and Mr. Lin Sen as executive Directors, Dr. Song Yuan, Mr. Wang Ruiqin, Ms. Chen Hongqin and Mr. Zhang Hong as non-executive Directors, and Mr. Jian Xigao, Mr. Hui Hung Kwan and Mr. Xu Congli as independent non-executive Directors.

* *For identification purposes only*